A Phase II study (NCI-9742) investigating the anti-tumor activity of nivolumab (an anti-PD1 mAb) in patients with multiply pretreated recurrent NPC. Better responses without unexpected toxicity were observed in patients bearing PD-L1 positive tumors. This evidence concerns the gene CD274 and neoplasm.